Xiaodong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaodong Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Gouping Ding
4 shared publicationsQianqian Wang
Department of Oncology Zhuzhou Hospital Affiliated to Xiangya School of Medicine Central South University Zhuzhou China
4 shared publicationsJunjie Wang
3 shared publications- Yeqian Feng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
3 shared publications Yixuan Tang
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine Central South University Zhuzhou China
3 shared publications- Bingwen Zou
Department of Radiation Oncology, Cancer Center & Institution of Stress Medicine, West China Hospital, Sichuan University, Chengdu, China
2 shared publications
Latest Publications
- 14 November 2026
- Published by Wiley in Advanced Materials
Materials Control of Nitric Oxide in Cancer Immunotherapy
Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune‐mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint‐treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant‐tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO‐dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.
- 14 November 2026
- Published by Wiley in Advanced Materials
Materials Control of Nitric Oxide in Cancer Immunotherapy
Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune‐mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint‐treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant‐tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO‐dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.
- 25 September 2026
- Published by Elsevier in Cancer Letters
- Vol. 661
Radiation-induced cell-death states in cancer: Toward biomarker-guided radioimmunotherapy
- 25 September 2026
- Published by Elsevier in Cancer Letters
- Vol. 661
Radiation-induced cell-death states in cancer: Toward biomarker-guided radioimmunotherapy
- Open Access
- 16 September 2026
- Published by Elsevier in Materials Today Advances
- Vol. 32
Cancer-associated fibroblast–tumor organoid models of therapy resistance: mechanisms, materials, and translational potential
- 16 September 2026
- Published by Elsevier in Materials Today Advances
- Vol. 32
Open AccessCancer-associated fibroblast–tumor organoid models of therapy resistance: mechanisms, materials, and translational potential
- Open Access
- 7 June 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (6) , e70197
Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching
Ovarian cancer peritoneal metastasis remains a major cause of recurrence and death despite advances in cytoreductive surgery, platinum‐based chemotherapy, PARP inhibition, and immune checkpoint blockade. The limited activity of immunotherapy in this setting reflects layered immune resistance shaped by impaired antigen visibility, redundant inhibitory receptor networks, suppressive myeloid and regulatory circuits, and metabolic‐epigenetic constraints within ascites and multicellular spheroids. These compartment‐specific features distinguish peritoneal disease from anatomically confined tumors and help explain why systemic immune reinvigoration alone rarely produces durable benefit. Here, we synthesize current evidence on the mechanisms that govern immune escape in ovarian cancer peritoneal dissemination, with emphasis on antigen presentation defects, checkpoint‐driven T‐cell exhaustion, anti‐phagocytic signaling, soluble suppressive mediators, and metabolic remodeling of the ascites microenvironment. We further examine how DNA damage response states intersect with innate immune sensing and discuss the translational implications of homologous recombination deficiency for combination treatment design. Finally, we propose a biomarker‐guided framework that links antigen‐presentation competence, immune engagement, dominant suppressive axes, and ascites‐specific biology to rational therapeutic matching. This mechanism‐centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.
- 7 June 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (6) , e70197
Open AccessImmune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching
Ovarian cancer peritoneal metastasis remains a major cause of recurrence and death despite advances in cytoreductive surgery, platinum‐based chemotherapy, PARP inhibition, and immune checkpoint blockade. The limited activity of immunotherapy in this setting reflects layered immune resistance shaped by impaired antigen visibility, redundant inhibitory receptor networks, suppressive myeloid and regulatory circuits, and metabolic‐epigenetic constraints within ascites and multicellular spheroids. These compartment‐specific features distinguish peritoneal disease from anatomically confined tumors and help explain why systemic immune reinvigoration alone rarely produces durable benefit. Here, we synthesize current evidence on the mechanisms that govern immune escape in ovarian cancer peritoneal dissemination, with emphasis on antigen presentation defects, checkpoint‐driven T‐cell exhaustion, anti‐phagocytic signaling, soluble suppressive mediators, and metabolic remodeling of the ascites microenvironment. We further examine how DNA damage response states intersect with innate immune sensing and discuss the translational implications of homologous recombination deficiency for combination treatment design. Finally, we propose a biomarker‐guided framework that links antigen‐presentation competence, immune engagement, dominant suppressive axes, and ascites‐specific biology to rational therapeutic matching. This mechanism‐centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 19, 1-20
Artificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance
Immune checkpoint inhibitors (ICIs) have reshaped oncology, yet overall response rates remain modest and resistance is common, driven by tumor heterogeneity and evolving tumor–immune crosstalk. Established biomarkers (PD-L1, tumor mutational burden, microsatellite instability) provide incomplete prediction. Multi-omics profiling across genomic, transcriptomic, proteomic, epigenomic, metabolomic and microbiomic layers offers a systems-level view of malignant and immune states, uncovering determinants of ICI efficacy such as lineage plasticity, stromal remodeling, immunometabolic reprogramming and microbiome-associated immune modulation. Artificial intelligence (AI) is uniquely positioned to fuse these heterogeneous data, learn non-linear cross-layer signatures, and enable interpretable predictions using approaches such as SHAP and Grad-CAM. Representative models link routine histology or imaging to molecular phenotypes, stratify patients beyond single biomarkers, and may nominate rational combinations that target oncogenic pathways, lactate-driven immune suppression, or the gut microbiome. In this narrative review, we synthesize recent AI–multi-omics advances for response modeling, immune-relevant tumor subtyping, and clinical translation, including radiomics/pathomics integration and liquid-biopsy–based monitoring, as well as emerging applications in toxicity risk prediction. We also discuss barriers to implementation—platform heterogeneity, limited prospective validation, bias, interpretability and cost—and outline future directions, including single-cell and spatial multi-omics integration, federated learning and generative modeling to improve robustness and equity of precision immunotherapy.
- 1 February 2026
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 19, 1-20
Open AccessArtificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance
Immune checkpoint inhibitors (ICIs) have reshaped oncology, yet overall response rates remain modest and resistance is common, driven by tumor heterogeneity and evolving tumor–immune crosstalk. Established biomarkers (PD-L1, tumor mutational burden, microsatellite instability) provide incomplete prediction. Multi-omics profiling across genomic, transcriptomic, proteomic, epigenomic, metabolomic and microbiomic layers offers a systems-level view of malignant and immune states, uncovering determinants of ICI efficacy such as lineage plasticity, stromal remodeling, immunometabolic reprogramming and microbiome-associated immune modulation. Artificial intelligence (AI) is uniquely positioned to fuse these heterogeneous data, learn non-linear cross-layer signatures, and enable interpretable predictions using approaches such as SHAP and Grad-CAM. Representative models link routine histology or imaging to molecular phenotypes, stratify patients beyond single biomarkers, and may nominate rational combinations that target oncogenic pathways, lactate-driven immune suppression, or the gut microbiome. In this narrative review, we synthesize recent AI–multi-omics advances for response modeling, immune-relevant tumor subtyping, and clinical translation, including radiomics/pathomics integration and liquid-biopsy–based monitoring, as well as emerging applications in toxicity risk prediction. We also discuss barriers to implementation—platform heterogeneity, limited prospective validation, bias, interpretability and cost—and outline future directions, including single-cell and spatial multi-omics integration, federated learning and generative modeling to improve robustness and equity of precision immunotherapy.